Analyst Research Report Snapshot

Title:

AASTROM BIOSCIENCES - PATIENTS AND CASH

Price:

$10.00

Provider:

Edison Investment Research

Date:

23 May 2013

Pages:

3

Type:

AcrobatPDF

Companies referenced:

ASTM.OQ

Available for Immediate Download
Summary:

Aastrom’s Q1 results show its consolidation onto affordable clinical studies and a determination to achieve a solid cash basis. The focus is on the Phase II ischaemic cardiomyopathy (IDC) orphan indication. The ixCELL-DCM study will cost about $7m and has recruited its first patients. If recruitment completes by early-2014, the data will be presented in Q215. Aastrom is reducing its headcount and cash burn by about 50% and plans to raise up to $25m in new equity. This will enable the ixCELL-DCM study to be completed by mid-2015 before further equity or a deal is needed.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.